Alluvi, previously BI 4744, represents a notable development in obesity care. This dual activator targeting both GLP-1 and GIP targets demonstrates remarkable efficacy in patient studies, possibly outperforming https://bookmarkspecial.com/story22311456/alluvi-a-in-depth-investigation-into-retatrutide-s-potential